SCHEMBL5651555

SCHEMBL5651555

CC(C)N[C@@H](CCC(N)=O)C(=O)OC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
MMP2 P08253 2/20 0.46
MMP9 P14780 2/20 0.46
SLC1A5 Q15758 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2247315 0.85 KDM4E (0.46) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL4357430 0.82 KDM4E (0.46) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL4365446 0.82 KDM4E (0.46) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL4621031 0.82 KDM4E (0.46) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL4356541 0.82 KDM4E (0.48) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL4364695 0.82 KDM4E (0.45) KDM4EMMP2MMP9SLC1A5KMT2A
SCHEMBL4369490 0.81 KDM4E (0.44) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL5654173 0.81 KDM4E (0.44) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL5652199 0.79 KDM4E (0.45) KDM4EPDCD1CD274MMP2MMP9
SCHEMBL5651929 0.79 PRMT5 (0.46) KDM4EPDCD1CD274MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 KDM4E 1232/4885PDCD1 2721/4885CD274 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.